Author: Paul Tardner Date published: 25/08/2020
Originally published at: IJEST Pull test PDF: View PDF
Abstract
Citicoline, also known as CDP-Choline (or less frequently Cognizin in its branded form) is a widely-used nootropic substance known for its ability to acutely increase acetylcholine availability in the brain. As it stands, citicoline is one of the most commonly used ingredients in pre-made natural nootropic supplements. Owing to the commonality of its use, people have become increasingly concerned about the safety of citicoline use, particularly when it is used on a daily basis for prolonged periods. Specifically, many people have become concerned that citicoline may cause lethargy, loss of motivation, and depression. In this article, we examine the available clinical literature on citicoline use as it related to mental illness, with a particular focus on depression.
Keywords: Citicoline, CDP-Choline, nootropics, depression
Works cited
[1] Fioravanti M, Buckley AE. Citicoline (Cognizin) in the treatment of cognitive impairment. Clin Interv Aging. 2006;1(3):247-251.
[2] Fioravanti M, Buckley AE. Citicoline (Cognizin) in the treatment of cognitive impairment. Clin Interv Aging. 2006;1(3):247-251.
[3] Silveri MM, Dikan J, Ross AJ, et al. Citicoline enhances frontal lobe bioenergetics as measured by phosphorus magnetic resonance
spectroscopy. NMR Biomed. 2008;21(10):1066-1075.
[4] Talih F, Ajaltouni J. Probable Nootropicinduced Psychiatric Adverse Effects: A Series of Four Cases. Innov Clin Neurosci. 2015;12(11-12):21-25. [5] Brown ES, Gabrielson B. A randomized, double-blind, placebo- controlled trial of citicoline for bipolar and unipolar depression and methamphetamine dependence. J Affect Disord. 2012;143(1- 3):257-260.